Immutep (ASX:IMM) reports 71.4% response rate for lung cancer therapy
b"31 Oct 2023 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress of the company's drug candidates, highlighting promising data from the 2023 ESMO Congress."